The Europe Minimal Residual Disease Testing Market would witness market growth of 14.0% CAGR during the forecast period (2022-2028).
Barriers to the application of biomarker testing alternatives are expanding along with their usage in the treatment of specific cancers. Lack of knowledge about how biomarker testing functions and what impact it can have on choosing the most effective cancer treatment options underlies these hurdles. Additionally, the morphologic evaluation of complete remission (presence of 5% or fewer blasts in bone marrow) is insufficient to detect residual malignant cells.
Conversely, MRD tests produce results with higher degrees of disease detection sensitivity. Monitoring of MRD gives a technique to precisely evaluate the early therapeutic efficacy and detect relapse in individuals with acute lymphoblastic leukemia (ALL).
The abnormal immunophenotypes’ detection by flow cytometry, PCR amplification of fusion transcripts, and PCR amplification of antigen-receptor genes are well-established techniques for studying MRD. In addition, it is widely known that there is a significant association between MRD concentrations and the probability of relapse in pediatric ALL.
The usage of minimal residual disease testing has gained a significant position in this region because of its advance prognostic importance for producing results and increasing the adoption of MRD diagnostics possibilities in treatment stratification. Therefore, the need for methodology standardization and terminology harmonization has increased exponentially in the region. Additionally, the prevalence of cancer is rising quickly in the region. Approximately 2.7 million people in the European Union received a diagnosis of the illness in 2020, and about 1.3 million people passed away as a result, according to the European Commission.
The Germany market dominated the Europe Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $181.2 million by 2028.The UK market is experiencing a CAGR of 13.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 14.8% during (2022 - 2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End User, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Minimal Residual Disease Testing Market will Hit $2.7 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Others
By End User
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F.Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Minimal Residual Disease Testing Market, by Application
1.4.2 Europe Minimal Residual Disease Testing Market, by End User
1.4.3 Europe Minimal Residual Disease Testing Market, by Technology
1.4.4 Europe Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Minimal Residual Disease Testing Market by Application
3.1 Europe Hematological Malignancies Market by Country
3.2 Europe Leukemia Market by Country
3.3 Europe Lymphoma Market by Country
3.4 Europe Solid Tumors Market by Country
3.5 Europe Others Market by Country
Chapter 4. Europe Minimal Residual Disease Testing Market by End User
4.1 Europe Hospitals & Specialty Clinics Market by Country
4.2 Europe Diagnostic Laboratories Market by Country
4.3 Europe Academic & Research Institutes Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Minimal Residual Disease Testing Market by Technology
5.1 Europe Polymerase Chain Reaction (PCR) Market by Country
5.2 Europe Next-Generation Sequencing (NGS) Market by Country
5.3 Europe Flow Cytometry Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Minimal Residual Disease Testing Market by Country
6.1 Germany Minimal Residual Disease Testing Market
6.1.1 Germany Minimal Residual Disease Testing Market by Application
6.1.2 Germany Minimal Residual Disease Testing Market by End User
6.1.3 Germany Minimal Residual Disease Testing Market by Technology
6.2 UK Minimal Residual Disease Testing Market
6.2.1 UK Minimal Residual Disease Testing Market by Application
6.2.2 UK Minimal Residual Disease Testing Market by End User
6.2.3 UK Minimal Residual Disease Testing Market by Technology
6.3 France Minimal Residual Disease Testing Market
6.3.1 France Minimal Residual Disease Testing Market by Application
6.3.2 France Minimal Residual Disease Testing Market by End User
6.3.3 France Minimal Residual Disease Testing Market by Technology
6.4 Russia Minimal Residual Disease Testing Market
6.4.1 Russia Minimal Residual Disease Testing Market by Application
6.4.2 Russia Minimal Residual Disease Testing Market by End User
6.4.3 Russia Minimal Residual Disease Testing Market by Technology
6.5 Spain Minimal Residual Disease Testing Market
6.5.1 Spain Minimal Residual Disease Testing Market by Application
6.5.2 Spain Minimal Residual Disease Testing Market by End User
6.5.3 Spain Minimal Residual Disease Testing Market by Technology
6.6 Italy Minimal Residual Disease Testing Market
6.6.1 Italy Minimal Residual Disease Testing Market by Application
6.6.2 Italy Minimal Residual Disease Testing Market by End User
6.6.3 Italy Minimal Residual Disease Testing Market by Technology
6.7 Rest of Europe Minimal Residual Disease Testing Market
6.7.1 Rest of Europe Minimal Residual Disease Testing Market by Application
6.7.2 Rest of Europe Minimal Residual Disease Testing Market by End User
6.7.3 Rest of Europe Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
TABLE 1 Europe Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 2 Europe Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 3 Europe Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 4 Europe Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 5 Europe Hematological Malignancies Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Hematological Malignancies Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Leukemia Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Leukemia Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Lymphoma Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Lymphoma Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Solid Tumors Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Solid Tumors Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 16 Europe Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 17 Europe Hospitals & Specialty Clinics Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Hospitals & Specialty Clinics Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Diagnostic Laboratories Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Diagnostic Laboratories Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Academic & Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Academic & Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 26 Europe Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 27 Europe Polymerase Chain Reaction (PCR) Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Polymerase Chain Reaction (PCR) Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Next-Generation Sequencing (NGS) Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Next-Generation Sequencing (NGS) Market by Country, 2022 - 2028, USD Million
TABLE 31 Europe Flow Cytometry Market by Country, 2018 - 2021, USD Million
TABLE 32 Europe Flow Cytometry Market by Country, 2022 - 2028, USD Million
TABLE 33 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 34 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 35 Europe Minimal Residual Disease Testing Market by Country, 2018 - 2021, USD Million
TABLE 36 Europe Minimal Residual Disease Testing Market by Country, 2022 - 2028, USD Million
TABLE 37 Germany Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 38 Germany Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 39 Germany Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 40 Germany Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 41 Germany Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 42 Germany Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 43 Germany Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 44 Germany Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 45 UK Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 46 UK Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 47 UK Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 48 UK Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 49 UK Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 50 UK Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 51 UK Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 52 UK Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 53 France Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 54 France Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 55 France Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 56 France Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 57 France Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 58 France Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 59 France Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 60 France Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 61 Russia Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 62 Russia Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 63 Russia Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 64 Russia Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 65 Russia Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 66 Russia Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 67 Russia Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 68 Russia Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 69 Spain Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 70 Spain Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 71 Spain Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 72 Spain Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 73 Spain Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 74 Spain Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 75 Spain Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 76 Spain Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 77 Italy Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 78 Italy Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 79 Italy Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 80 Italy Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 81 Italy Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 82 Italy Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 83 Italy Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 84 Italy Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
TABLE 87 Rest of Europe Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
TABLE 88 Rest of Europe Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
TABLE 89 Rest of Europe Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
TABLE 90 Rest of Europe Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
TABLE 91 Rest of Europe Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
TABLE 92 Rest of Europe Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
TABLE 93 Key Information – Bio-Rad Laboratories, Inc.
TABLE 94 Key Information – Guardant Health, Inc.
TABLE 95 Key Information – Invitae Corporation
TABLE 96 Key Information – Bio-Techne Corporation
TABLE 97 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 98 Key Information – ICON PLC
TABLE 99 Key Information – Natera Inc.
TABLE 100 key information – Sysmex Corporation
TABLE 101 Key Information – Laboratory Corporation of America holdings
TABLE 102 Key Information – Invivoscribe, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Guardant Health, Inc.
FIG 3 Recent strategies and developments: Laboratory corporation of America Holding